News
News
T-1101 Receives FDA Approval to Advance to Phase II Clinical Trial, Marking a Significant Milestone
Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. This trial will further evaluate the safety and efficacy of T-1101 in patients with neuroendocrine tumors (NET), laying a solid foundation for future regulatory submissions. T-1101 is the first-in-class oral small-molecule inhibitor targeting Hec1/Nek2, developed to treat …
Taivex’s ‘s T-1101 and T-1201 Invited to Present Study Progress at KSMO 2024 Annual Meeting
Taivex announced that its Phase I clinical trial drugs, T-1101 and T-1201, have been invited to present their project progress at the Korean Society of Medical Oncology (KSMO) 2024 Annual Meeting. The company will unveil the unique properties of these innovative therapies and their clinical trial designs, highlighting their potential impact on cancer treatment. The KSMO Annual Meeting brings …
Taivex Therapeutics Corporation will attend Bio Asia-Taiwan 2024
Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Taivex will attend the Bio Asia-Taiwan 2024, BIO One-on-One PartneringTM to seek for potential collaboration partner for licensing out or co-development opportunities. T-1101 is a First-in-Class oral capsule formulation. The enrollment of study subject of T-1101 Phase I clinical trial has been completed …
Groundbreaking Cancer Treatments T-1201 and T-1301 to be Presented at WCC-2024
The groundbreaking discovery and development of T-1201, a novel targeting small molecule-drug conjugate (SN38), and T-1301, an innovative multi-targeted tyrosine kinase inhibitor (TKI), have been selected for an oral presentation at the prestigious 16th Annual World Cancer Congress (WCC-2024).
